Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$903M |
| 2 |
Charles Schwab
SCHW
|
$631M |
| 3 |
Affirm
AFRM
|
$556M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
$514M |
| 5 |
Coupang
CPNG
|
$458M |
Top Sells
| 1 |
Tesla
TSLA
|
$3.23B |
| 2 |
Full Truck Alliance
YMM
|
$995M |
| 3 |
ResMed
RMD
|
$718M |
| 4 |
NVIDIA
NVDA
|
$691M |
| 5 |
Amazon
AMZN
|
$509M |
Sector Composition
| 1 | Consumer Discretionary | 26.58% |
| 2 | Healthcare | 23.23% |
| 3 | Technology | 21.05% |
| 4 | Communication Services | 12.81% |
| 5 | Financials | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCNA
251
NuCana
NCNA
$5.48M
| $8.71M | ﹤0.01% |
732
| – | – |
|
252
BridgeBio Pharma
BBIO
$10.2B
| $8.17M | ﹤0.01% |
489,721
+23,845
| +5% | +$398K |
|
253
Allbirds
BIRD
$51M
| $8.03M | ﹤0.01% |
+26,625
| New | +$8.03M |
|
|
OCFT
254
OneConnect Financial Technology
OCFT
$281M
| $7.47M | ﹤0.01% |
302,444
+5,129
| +2% | +$127K |
|
255
Fortive
FTV
$16.2B
| $7.46M | ﹤0.01% |
97,814
| – | – |
|
256
Alector
ALEC
$305M
| $7.43M | ﹤0.01% |
359,724
+19,372
| +6% | +$400K |
|
257
Relay Therapeutics
RLAY
$710M
| $6.91M | ﹤0.01% |
225,041
+11,952
| +6% | +$367K |
|
258
TJX Companies
TJX
$155B
| $6.6M | ﹤0.01% |
86,893
| – | – |
|
|
MTLS
259
Materialise
MTLS
$292M
| $6.4M | ﹤0.01% |
+268,000
| New | +$6.4M |
|
260
Lyell Immunopharma
LYEL
$233M
| $5.6M | ﹤0.01% |
36,169
+14,795
| +69% | +$2.29M |
|
|
SAGE
261
DELISTED
Sage Therapeutics
SAGE
| $3.85M | ﹤0.01% |
90,372
+4,074
| +5% | +$173K |
|
262
American Well
AMWL
$113M
| $3.74M | ﹤0.01% |
30,964
+5,836
| +23% | +$705K |
|
|
SOHU
263
Sohu.com
SOHU
$467M
| $3.26M | ﹤0.01% |
200,140
| – | – |
|
264
Adicet Bio
ACET
$60M
| $3.18M | ﹤0.01% |
181,626
| – | – |
|
265
Spire Global
SPIR
$276M
| $2.93M | ﹤0.01% |
108,256
| – | – |
|
|
UXIN
266
Uxin Ltd
UXIN
$722M
| $2.81M | ﹤0.01% |
17,761
| – | – |
|
267
Axogen
AXGN
$735M
| $2.36M | ﹤0.01% |
251,435
-910,224
| -78% | -$8.53M |
|
|
KLDO
268
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $1.72M | ﹤0.01% |
721,512
+62,285
| +9% | +$149K |
|
269
WEC Energy
WEC
$34.7B
| $1.71M | ﹤0.01% |
17,566
+2,333
| +15% | +$226K |
|
270
Exelon
EXC
$43.9B
| $1.52M | ﹤0.01% |
36,866
+5,646
| +18% | +$233K |
|
271
Fortis
FTS
$24.8B
| $1.51M | ﹤0.01% |
31,332
+875
| +3% | +$42.3K |
|
272
Novanta
NOVT
$4.18B
| $1.27M | ﹤0.01% |
7,176
+6,970
| +3,383% | +$1.23M |
|
273
Newmont
NEM
$83.7B
| $1.25M | ﹤0.01% |
20,172
| – | – |
|
274
Xencor
XNCR
$610M
| $1.18M | ﹤0.01% |
29,307
+28,048
| +2,228% | +$1.13M |
|
275
Summit Therapeutics
SMMT
$19.3B
| $1.17M | ﹤0.01% |
436,512
| – | – |
|